Peer-review started: February 8, 2021
First decision: March 29, 2021
Revised: April 14, 2021
Accepted: December 31, 2021
Article in press: December 31, 2021
Published online: January 27, 2022
Processing time: 347 Days and 0.8 Hours
Core Tip: Elimination of hepatitis C virus (HCV) by 2030 according to the World Health Organization policy seems highly unlikely because of the funding re-direction due to the coronavirus disease 2019 pandemic. It is important therefore to re-evaluate the treatment policies based on a more realistic and feasible approach. HCV disease has a very prolonged natural course, and even HCV-related cirrhosis has a lower mortality compared to other cirrhosis etiologies. However, liver related morbidity and mortality is increased when certain comorbidities accompany the initial HCV infection. A review of the current knowledge allows for a more or less accurate identification of these comorbidities. Therefore, an eradication program is proposed based on screening and treating only these particular groups.